Lung Cancer Surgery Market Is Booming Worldwide at a CAGR of 7% BY 2023 | ACCURAY, ETHICON, GE HEALTHCARE, JOHNSON & JOHNSON, OLYMPUS, RICHARD WOLF AND SIEMENS HEALTHCARE

Global Lung Cancer Surgery Market Highlights
The Lung cancer surgery Market is expected to register a CAGR of about 7%, during the forecast period, 2018 to 2023. Lung Cancer is the lethal lung tumor portrayed by the undisciplined growth of cells in the lung tissues.

Get your sample report now @ https://marketprognosis.com/sample-request/17054
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Rise in the Level of Air Pollution
According to a recent report, lung cancer constitutes 6.9% of all new cancer cases and 9.3% of all cancer-related deaths in both men and women. The two main types of carcinomas are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). About 10% to 15% of non-smokers are also at risk. The WHO's International Agency for Research on Cancer has classified outdoor air pollution as a carcinogen. Rising levels of pollution are leading to increased incidences of lung cancer. This acts as a driver for the market of lung cancer surgery. Along with this, majority of lung cancer cases are a result of long-term tobacco smoking. With the rising number of smokers, more people are getting affected by lung cancer. Also, the technological advancements in the field of lung cancer surgery and rise in incidences of lung cancer will together act as drivers for the lung cancer surgery market.

Key Developments in the Market
November 2017 - Sysmex Acquired CLIA Waiver for New Automated Lung cancer surgery Analyzeru2014The First Automated Lung cancer surgery Analyzer to Receive Such Approval.

Major Players:
ACCURAY, ETHICON, GE HEALTHCARE, JOHNSON & JOHNSON, OLYMPUS, RICHARD WOLF AND SIEMENS HEALTHCARE, amongst others.

Get Discount on this report @ https://marketprognosis.com/discount-request/17054
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Effective Alternative Treatment
Surgery has been the most prescribed form of treatment for patients with stage I non-small cell lung cancer. However, with the association of morbidity and mortality with surgery in the geriatric population remain a matter of concern. Along with this, the 5-year survival rates are also poor. However, with the availability of newer nonsurgical treatment options such as stereotactic radiation therapy (SRT) and radiofrequency ablation (RFA) the patients are considering opting for these treatment options. This acts as a restraining factor the lung cancer surgery market.

North America to Substantial Growth in the Market
North America will dominate the lung cancer surgery market due to the technological advancements in the field of lung cancer surgery. Europe will also show substantial growth in lung cancer surgery market as there is an increasing incidences of lung diseases. APAC consists of most of the countries with poor pollution regulations and major cities in countries, like China, India and Indonesia to be highly polluted, causing lung cancer in a huge population. Therefore, there will be a considerable growth in the lung cancer surgery market.

For More Information, Please Visit @ https://marketprognosis.com/enquiry/17054
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.